WO2006016682A1 - 血管弾力性改善剤およびその使用 - Google Patents
血管弾力性改善剤およびその使用 Download PDFInfo
- Publication number
- WO2006016682A1 WO2006016682A1 PCT/JP2005/014864 JP2005014864W WO2006016682A1 WO 2006016682 A1 WO2006016682 A1 WO 2006016682A1 JP 2005014864 W JP2005014864 W JP 2005014864W WO 2006016682 A1 WO2006016682 A1 WO 2006016682A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sesamin
- elasticity
- blood
- vascular
- improving
- Prior art date
Links
- 210000004204 blood vessel Anatomy 0.000 title abstract description 61
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract description 63
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 58
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims abstract description 54
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000002792 vascular Effects 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 17
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 description 36
- 230000017531 blood circulation Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- -1 lignan compounds Chemical class 0.000 description 8
- 230000035488 systolic blood pressure Effects 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 5
- 241000207961 Sesamum Species 0.000 description 5
- 235000003434 Sesamum indicum Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 235000014121 butter Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 229940126672 traditional medicines Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical class C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- HYKQSAMEQTXOBX-UHFFFAOYSA-N 1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan Chemical compound C1OCC2COCC21 HYKQSAMEQTXOBX-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- ZZMNWJVJUKMZJY-AFHBHXEDSA-N Sesamolin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-AFHBHXEDSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-UHFFFAOYSA-N Sesamolin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100001011 cardiovascular lesion Toxicity 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to improving blood vessel elasticity using sesamin and / or epicesamine.
- arteriosclerosis is a major cause of death in Japan as well as cancer, it is necessary to accurately evaluate asymptomatic arteriosclerosis that has not developed cardiovascular lesions to prevent cardiovascular disease from developing. It is very important to take measures against non-disease (Motoo Miyakojima, Journal of Japan Mibyou System Association, 4 (1), 8-11 (1998)). In addition, many epidemiological studies have shown that atherosclerotic lesions develop significantly after menopause in women (Kannel W B et al., Ann Intern Med, 854: 447-52, (1976)).
- Physiologically non-invasive assessment of vascular disease includes ankle brachial pressure index (ABI), toe pressure measurement, pulse wave velocity (PWV) (In fact, non-invasive diagnosis of blood vessels for cardiologists and laboratory technicians, Bunkodo (2001)).
- PWV is the speed at which the pulsation that occurs in a blood vessel with a single heartbeat travels to the periphery.
- the pulsatility index is a method that evaluates the dynamics of blood vessels based on changes in blood flow velocity measured by a Doppler, and is an index that reflects the elasticity of blood vessels. (Strandness DE. Et al., Prog Cardio vase Dis., 20, 403-22, (1978), Gosling RG et al., Angiology, 11, 52-5 (1971)) . The PI value decreases as blood vessel hardening progresses.
- PI values and PWV values have been confirmed to be inversely correlated (Moritani T et al., Med Sci Sports Exerc. 19, 404-409, (1987)), both of which are indicators of vessel stiffness and elasticity. It turns out to be useful.
- Augment at ion index (Al) which uses the magnitude of the reflected wave of the systolic blood pressure wave as an index, has attracted attention as a new blood vessel hardness and elasticity index (Ronan P et al. Hypertension 1429-1433 ( 2001)).
- symptomatic treatment is being performed for diseases that increase the risk.
- diseases that increase the risk For example, cholesterol-lowering drugs or triglyceride-lowering drugs are used for hyperlipidemia, anti-hypertensive drugs are used for hypertension, and blood sugar-lowering drugs are used for developing diabetes.
- the progression of atherosclerosis is the cause of these diseases Not only that, but the part caused by the blood vessels becoming harder with age is large. Nevertheless, no drug has been known to date that directly reduces or improves vascular sclerosis. Therefore, there has been a need for a safe pharmaceutical product or health food that can act directly on blood vessels, reduce blood vessel stiffness, and increase the elasticity of blood vessels.
- Sesamin is one of the main lignan compounds contained in sesame, and it is contained in sesame in an amount of 0.1-1%. Sesamin inhibits ⁇ 5 desaturase (S. Shimizu et al, J. Am. Oil Chem. So, 66, 237-241).
- JP 08-268887 discloses the antihypertensive effect of sesamin, and it has been reported that it exhibits a blood pressure lowering effect on the D0CA salt-loaded hypertension model and the renal clip renal hypertension model (Y. Matsumura et al., Biol. Parm. Bull., 18, 1016 (1995), S. Kita et al., Biol. Pharm. Bull., 18, 1283 (1995)). Also, stroke-prone hypertension It has been shown to suppress spontaneous rat (SHR-SP) (Y. Mat sumura et al., Biol. Pharm. Bull., 21, 469 (1998)).
- An object of the present invention is to provide a natural and safe composition that can relieve the hardness and elasticity of blood vessels and can prevent or improve diseases caused by the hardening of blood vessels.
- Methods for non-invasive assessment of vascular disease include ankle brachial pressure index (ABI), toe pressure measurement, pulse wave velocity (PWV), blood
- the power s can be listed as a flow wave index (Pul sat i 1 i ty index; PI) and augmentation index (AI).
- PWV, PI, and AI are used as indicators of vessel hardness and elasticity.
- the PI value evaluates the elasticity of the blood vessel from the change in blood flow velocity waveform measured by the Doppler method, and is expressed as the maximum blood flow velocity divided by the average blood flow velocity (Gosling RG et al., Angiology 22, 52-5 (1971)).
- PWV is the speed at which the pulsation that occurs in the blood vessel with a single heartbeat proceeds to the terminal tree.
- PWV is another method that can quantify the stiffness of arteries.
- sesamin and Z or its analogs which are sesame lignans, have the effect of improving the hardness of the blood vessels, that is, the elasticity. Clarified and completed the present invention.
- the present invention provides a vascular elasticity improving agent comprising sesamin and / or epicesamine as an effective component.
- the present invention also provides a blood vessel elasticity improving agent comprising sesamin and Z or epicesamine as an active ingredient, which has a blood vessel elasticity improving action that prevents, ameliorates or alleviates symptoms caused by vascular sclerosis.
- the above-mentioned vascular elasticity improving agent is provided, for example, in the form of a food or drink or a medicine.
- the invention also relates to the use of sesamin and / or epicesamine for the manufacture of a vascular elasticity improving agent.
- the present invention also relates to the use of sesamin and / or epicesamine for the production of a vascular elasticity improving agent that prevents, ameliorates or alleviates symptoms caused by vascular sclerosis.
- the vascular elasticity improving agent is, for example, a food or drink or a medicine.
- the invention further provides a method of improving vascular elasticity comprising administering sesamin and Z or epicesamine.
- the present invention further provides a method comprising administering sesamin and / or epicesamine in a method for improving vascular elasticity to prevent, ameliorate or alleviate symptoms caused by vascular sclerosis.
- sesamin and / or epicesamine are administered, for example, in the form of food or drink or medicine.
- This method is also used to improve vascular elasticity and prevent, ameliorate, or alleviate symptoms caused by vascular stiffness.
- FIG. 1 is a diagram showing the difference in blood pressure waveform between normal blood vessels and sclerosing blood vessels.
- Figure 2 shows the improvement effect of sesame on vascular elasticity using the blood pressure wave index as an index.
- Fig. 3 is a diagram showing the improvement effect of sesame on vascular elasticity using the pulse wave velocity (PWV) as an index.
- PWV pulse wave velocity
- the blood flow wave index (P I) is used to evaluate the elasticity of blood vessels from the blood flow velocity waveform obtained by Doppler measurement, and is indicated by the value obtained by dividing the maximum blood flow velocity by the average blood flow velocity (P I value). If the elasticity of the blood vessel is excellent, the volume of ejected blood from the heart increases rapidly due to the contraction of the left ventricle, and the blood flow velocity increases accordingly. After that, if the heart relaxes, the ejection amount of the heart decreases at a stretch. If the blood vessel is hardened, it is difficult for the blood vessel to expand according to the blood volume, and because it flows through a narrow blood vessel, the blood flow is very fast, and the blood ejected from the heart also during relaxation It will flow at a high speed.
- the average blood flow velocity increases when the blood vessel is hardened, and the value obtained by dividing the maximum blood flow velocity by the average blood flow velocity (P I value) is small.
- P I value the average blood flow velocity
- the blood vessels dilate according to the volume of blood, so the flow of blood is smooth, and when relaxed, the blood flow velocity decreases all at once, so the PI value increases.
- Blood pressure is the pressure that blood exerts on the blood vessel wall by the pumping action of the heart. Therefore, we focused on the fact that the same principle as the blood flow wave index can be applied to blood pressure, and decided to evaluate the elasticity of blood vessels from continuously measured blood pressure waveforms.
- Figure 1 shows the blood pressure waveform It is.
- the aorta opens due to an increase in the left ventricular pressure due to the contraction of the left ventricle and blood is ejected, the aortic pressure rises rapidly and reaches the maximum blood pressure (systolic blood pressure) Ps.
- the aortic pressure rises rapidly and reaches the maximum blood pressure (systolic blood pressure) Ps.
- the left ventricular pressure drops at the end of systole and the aortic valve closes
- the aortic pressure begins to drop rapidly and reaches the lowest blood pressure (diastolic blood pressure) Pd.
- the blood vessel dilates in response to an increase in blood flow, so the blood pressure decreases rapidly after reaching the maximum blood pressure (Fig. 1 A).
- the value calculated by the formula of systolic blood pressure / mean blood pressure is an indicator of the elasticity of the blood vessel.
- the maximum blood pressure is not a problem, and what is the average blood pressure calculated from the waveform shows the maximum blood pressure.
- the value, that is, the systolic blood pressure / average blood pressure value can be regarded as an index of blood vessel elasticity as a blood pressure wave index.
- the present inventor aims to find an excellent compound having an effect of improving the vascular elasticity, and uses various blood pressure, blood pressure index (systolic blood pressure / average blood pressure) as an index, and various foods, food ingredients, and traditional medicines.
- blood pressure index systolic blood pressure / average blood pressure
- sesamin improves the elasticity of blood vessels.
- PWV blood pressure index
- sesamin is It was confirmed that it has the effect of improving the elasticity of the tube. In other words, it has been clarified that sesamin has a blood vessel elasticity improving effect.
- the present invention intends to provide a food and drink having an effect of improving vascular elasticity, and a method for using the same, comprising sesamin and Z or an analog thereof as active ingredients. More specifically, it improves the hardening of blood vessels with age and the hardening of blood vessels due to various factors to prevent symptoms and diseases caused by hardening of blood vessels, vascular disorders, cardiovascular diseases, and arteriosclerotic diseases. It is intended to provide foods and beverages that can be improved and how to use them.
- sesamin and its analogs mean, for example, dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331. Specifically, sesamin, sesaminool.
- sesamin and its analogs in the present invention are: For example, these can be obtained by the method described in JP-A No. 4-19331, and these can be used as an extract or as a purified product if necessary.
- sesamin and / or an analog thereof when using sesamin and / or an analog thereof as a vascular elasticity improving agent in the present invention, it contains not only a health food and drink containing sesamin and / or an analog thereof, but also sesamin and Z or an analog thereof.
- the food additive formed is also included.
- a health food or drink for example, it can be added to dried foods, supplements, soft drinks, mineral water, alcoholic beverages, etc., but is not limited thereto.
- the preparation may be solid or liquid, and powder, tablet, pill, capsule, suppository, granule, liquid for internal use, suspension And emulsions and lotions.
- excipients that are pharmaceutically acceptable can be added to the preparation of the present invention.
- a diluent, a fragrance, a stabilizer, a lubricant for suspension, a binder, a preservative, a disintegrant for tablets, etc. can be used alone or in combination.
- the amount of sesamin of the present invention and / or its analog (active ingredient) required to improve vascular elasticity is 1 OmgZ in adults, but this effective amount is a factor that causes vascular sclerosis, disease Depends on type, patient characteristics, age, weight, symptom severity, and dosage form.
- the effective amount for sesamin and rosin or its analogs to have an effect of improving vascular elasticity is, for example, 0.5 to 100 mg, preferably 1 to 6 O mg, more preferably 5 to 60 per day.
- sesamin and / or its analogs which are the active ingredients of foods and drinks and pharmaceuticals of the present invention, are preferably used. It is desirable to take it continuously for a long time.
- the time and form of ingestion are not limited, and it can improve the elasticity of blood vessels by ingesting at various occasions.
- Example 1 Effect of improving blood vessel elasticity using blood pressure wave index as an index 14 middle-aged women (mean age 52 years) were used in a double-blind parallel group comparison study as a control. The subjects were randomly divided into two groups, one group receiving 3 soft capsules containing sesamin (Sesamin l OmgZ day) and the other group receiving 3 placebo capsules for 4 weeks. I let you. Before and after sample intake, blood pressure was measured continuously for 4 minutes using a FINAPRESS, and the obtained blood pressure waveform was analyzed, and the mean blood pressure was obtained as the average value over 4 minutes from the systolic blood pressure and the area value of the blood pressure waveform. It was. The blood pressure wave index was calculated by the following formula. The higher the value, the better the elasticity of the blood vessel, and the lower the value, the poorer the elasticity of the blood vessel.
- Bloodsho wave index systolic blood pressure / mean blood pressure
- the maximum blood pressure before ingestion was 98.8 mmHg in the sesamin group, 104.7 MiHg in the placebo group, 102.3 mmHg in the sesamin group after ingestion, and 10 4.8 mmHg in the placebo group. I could't.
- the blood pressure wave index was 1.30 in the placebo group and 1.31 in the sesamin group before ingestion. After taking the sample for 1 month, there was almost no change at 1.34 in the placebo group, while there was a significant increase at 1.39 in the sesamin intake group (Fig. 2). )
- Example 2 Improvement of vascular elasticity using pulse wave velocity as an index The test was performed on a cross-over evening for 24 subjects (average age 49 years) (double-blind method). A sesamin-containing capsule (sesamin 60 mg / day) or a placebo capsule was ingested for 4 weeks, and the PWV value (Form PWV / AB I BP-203RPE manufactured by Nippon Korin Co., Ltd.) was measured before and after that. After 4 weeks washout, the samples were changed and ingested again for 4 weeks, and changes in PWV values before and after taking sesamin were measured.
- PWV value Form PWV / AB I BP-203RPE manufactured by Nippon Korin Co., Ltd.
- FIG 3 shows the change in PWV value (A PWV).
- the PWV value decreased when taking sesamin (1442 ⁇ 1383 cm / s).
- sesamin has the effect of improving vascular elasticity.
- Gaic anhydride 2 0.5 g
- the following composition was filled in the soft capsule skin made of the above components by a conventional method to obtain a soft capsule of 200 mg per capsule.
- Vitamins Vitamin C 10 g
- Ingestion of sesamin and Z or its analogs can improve vascular elasticity.
- the effect of improving vascular elasticity is extremely useful in preventing and alleviating sclerosis of blood vessels due to various factors including aging.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004232248 | 2004-08-09 | ||
JP2004-232248 | 2004-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006016682A1 true WO2006016682A1 (ja) | 2006-02-16 |
Family
ID=35839437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/014864 WO2006016682A1 (ja) | 2004-08-09 | 2005-08-08 | 血管弾力性改善剤およびその使用 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006016682A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114013A1 (ja) * | 2006-03-31 | 2007-10-11 | Suntory Limited | リグナン類化合物含有組成物 |
US7943663B2 (en) | 2005-09-30 | 2011-05-17 | Suntory Holdings Limited | Process and an apparatus for producing episesamin-rich compositions |
WO2020003363A1 (ja) * | 2018-06-25 | 2020-01-02 | 学校法人近畿大学 | ニコチン摂取の影響による血管の劣化を防止するための健康食品または医薬組成物 |
WO2023223943A1 (ja) * | 2022-05-16 | 2023-11-23 | サントリーホールディングス株式会社 | 血管内皮機能改善用組成物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0551388A (ja) * | 1991-08-23 | 1993-03-02 | Suntory Ltd | 過酸化脂質生成抑制剤 |
JPH06227977A (ja) * | 1993-02-01 | 1994-08-16 | Suntory Ltd | 活性酸素消去剤 |
JPH08268887A (ja) * | 1995-02-01 | 1996-10-15 | Suntory Ltd | 高血圧症又はそれに起因する医学的症状の予防又は改善剤 |
JPH11246427A (ja) * | 1998-03-04 | 1999-09-14 | Kadoya Sesami Mills Inc | 糖・脂質代謝活性化剤 |
JP2001139579A (ja) * | 1999-11-18 | 2001-05-22 | Suntory Ltd | リグナン系抗酸化剤及びその製造法 |
-
2005
- 2005-08-08 WO PCT/JP2005/014864 patent/WO2006016682A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0551388A (ja) * | 1991-08-23 | 1993-03-02 | Suntory Ltd | 過酸化脂質生成抑制剤 |
JPH06227977A (ja) * | 1993-02-01 | 1994-08-16 | Suntory Ltd | 活性酸素消去剤 |
JPH08268887A (ja) * | 1995-02-01 | 1996-10-15 | Suntory Ltd | 高血圧症又はそれに起因する医学的症状の予防又は改善剤 |
JPH11246427A (ja) * | 1998-03-04 | 1999-09-14 | Kadoya Sesami Mills Inc | 糖・脂質代謝活性化剤 |
JP2001139579A (ja) * | 1999-11-18 | 2001-05-22 | Suntory Ltd | リグナン系抗酸化剤及びその製造法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943663B2 (en) | 2005-09-30 | 2011-05-17 | Suntory Holdings Limited | Process and an apparatus for producing episesamin-rich compositions |
WO2007114013A1 (ja) * | 2006-03-31 | 2007-10-11 | Suntory Limited | リグナン類化合物含有組成物 |
US9408803B2 (en) | 2006-03-31 | 2016-08-09 | Suntory Holdings Limited | Compositions containing lignan-class compounds |
WO2020003363A1 (ja) * | 2018-06-25 | 2020-01-02 | 学校法人近畿大学 | ニコチン摂取の影響による血管の劣化を防止するための健康食品または医薬組成物 |
JPWO2020003363A1 (ja) * | 2018-06-25 | 2021-06-24 | 学校法人近畿大学 | ニコチン摂取の影響による血管の劣化を防止するための健康食品または医薬組成物 |
JP7244024B2 (ja) | 2018-06-25 | 2023-03-22 | 学校法人近畿大学 | ニコチン摂取の影響による血管壁のコラーゲン分解防止剤 |
WO2023223943A1 (ja) * | 2022-05-16 | 2023-11-23 | サントリーホールディングス株式会社 | 血管内皮機能改善用組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2361740T3 (es) | Composiciones que comprenden vitamina k para prevenir la hipertensión, la hipertrofia ventricular izquierda, la insuficiencia cardíaca congestiva, el infarto de miocardio, la apoplejía y la enfermedad cardíaca coronaria mediante la prevención de la rigidización arterial relacionada con la edad. | |
JP2004517148A (ja) | 心機能不全および心不全の治療における必須n−3脂肪酸 | |
JP2015155408A (ja) | 血行動態改善剤 | |
Nestel et al. | Arterial stiffness is rapidly induced by raising the plasma homocysteine concentration with methionine | |
WO2006016682A1 (ja) | 血管弾力性改善剤およびその使用 | |
CA2810732A1 (en) | Compositions and method for improving endothelial function and cardiovascular health | |
US20060058376A1 (en) | Composition having autonomic nerve modulating activity and method of use thereof | |
JP2011073973A (ja) | 更年期のための疲労改善組成物 | |
US11931396B2 (en) | Composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels | |
AU2004206156B2 (en) | Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto | |
WO2015046377A1 (ja) | 膀胱・尿道協調不全改善剤 | |
JP2012158603A (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
Eisalo et al. | HAEMODYNAMIC EFFECTS OF TRASICOR®, A NEW BETA‐ADRENERGIC BLOCKING AGENT, IN HYPERTENSIVE PATIENTS | |
JP4577998B2 (ja) | 尿酸値低下剤 | |
JP2020186205A (ja) | 血管拡張剤 | |
JP5783699B2 (ja) | 経口組成物 | |
KR20190012650A (ko) | 리나릴 아세테이트를 포함하는 올메사탄으로 유발된 빈맥의 예방 또는 치료용 조성물 | |
WO2024135348A1 (ja) | 動脈スティフネス増大抑制剤 | |
CN112656874A (zh) | 改善血管内皮细胞功能的组合物及用途 | |
WO2024019171A1 (ja) | 眼血流改善用組成物 | |
Kisters et al. | MAGNESIUM SUPPLEMENTATION REDUCES INERLEUKIN-6 AND BLOOD PRESSURE IN METABOLIC SYNDROME | |
Koh et al. | CARDIORESPIRATORY FITNESS, HIGH BODY FAT PERCENTAGE AND THE RISK OF CORONARY CALCIFICATION IN MIDDLE–AGED MEN | |
Kim | THE IMPACT OF OBESITY ON CARDIOVASCULAR RISK IN PATIENTS WITH PRESERVED EJECTION FRACTION: INSIGHTS FROM CENTRAL BLOOD PRESSURE ANALYSIS | |
Keller | Aged Garlic Extract Reduces Blood Pressure in Patients with Hypertension. | |
Dengel et al. | Vascular Function Across the Lifespan: The Role of Lifestyle Medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |